Polymorphisms Contribution to the Determination of Significant Risk of Specific Toxicities in Multiple Myeloma

Summary

The introduction of new drugs improved clinical response of patients with diagnosed multiple myeloma (MM); however, MM is still an incurable disease that leads to frequent relapses. Individual genetic variability can significantly affect therapeutic response, sensitivity and toxicity. Analysis of single nucleotide polymorphisms (SNPs) to study genetic changes is the genomic method that can obtain information for improving the effectiveness of treatment with minimum undesirable toxicity followed by individual treatments. The aim of this paper is to explain the possibility of detection and evaluation of polymorphisms associated with toxicity of treatment in patients with MM.

Key words:
single nucleotide polymorphisms (SNPs) – genotyping – real-time PCR – allelic discrimination – 
toxicity – multiple myeloma



This work was supported by research grants of The Ministry of Education, Youth and Sports: LC06027, MSM0021622434; research projects of IGA of The Ministry of Health: NS10207, NS10406, NT11154 and grant of GACR GAP304/10/1395.



The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.



The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.